Literature DB >> 16510039

Autoimmune hepatitis: diagnosis, treatment, and prognosis.

Bruce A Luxon1.   

Abstract

Autoimmune hepatitis (AIH) is an idiopathic hepatitis of unknown cause characterized by histologic evidence of chronic inflammation, liver autoantibodies, and increased gamma globulins in the serum. The clinical manifestations of AIH have been known since the 1950s and are essentially unchanged over the past 50 years. The cornerstone of therapy for AIH is immunosuppression using prednisone and azathioprine, with the vast majority of patients achieving clinical remission. This review provides a concise summary of the diagnostic criteria for AIH, describes its proposed pathogenic mechanisms and epidemiology, and offers an algorithmic approach to its initial treatment and follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16510039     DOI: 10.1007/s11894-006-0068-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  26 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  Autoimmune cholangitis within the spectrum of autoimmune liver disease.

Authors:  A J Czaja; H A Carpenter; P J Santrach; S B Moore
Journal:  Hepatology       Date:  2000-06       Impact factor: 17.425

3.  Recurrent autoimmune hepatitis after orthotopic liver transplantation.

Authors:  A González-Koch; A J Czaja; H A Carpenter; S K Roberts; M R Charlton; M K Porayko; C B Rosen; R H Wiesner
Journal:  Liver Transpl       Date:  2001-04       Impact factor: 5.799

4.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

5.  Meeting report: International Autoimmune Hepatitis Group.

Authors:  P J Johnson; I G McFarlane
Journal:  Hepatology       Date:  1993-10       Impact factor: 17.425

6.  Relapse following treatment withdrawal in autoimmune chronic active hepatitis.

Authors:  A J McCullough; A J Czaja
Journal:  Hepatology       Date:  1984 Jul-Aug       Impact factor: 17.425

7.  Anti-mitochondrial type 5 antibodies and anti-cardiolipin antibodies in systemic lupus erythematosus and auto-immune diseases.

Authors:  O Meyer; N Abuaf; L Cyna; J C Homberg; M F Kahn; A Ryckewaert
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

8.  Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.

Authors:  A J Czaja
Journal:  J Hepatol       Date:  1999-03       Impact factor: 25.083

9.  Genetic distinctions between types 1 and 2 autoimmune hepatitis.

Authors:  A J Czaja; M Kruger; P J Santrach; S B Moore; M P Manns
Journal:  Am J Gastroenterol       Date:  1997-12       Impact factor: 10.864

10.  Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.

Authors:  A J Czaja; H A Carpenter
Journal:  Gastroenterology       Date:  1993-12       Impact factor: 22.682

View more
  1 in total

1.  Role of myeloid-derived suppressor cells in amelioration of experimental autoimmune hepatitis following activation of TRPV1 receptors by cannabidiol.

Authors:  Venkatesh L Hegde; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  PLoS One       Date:  2011-04-01       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.